EAPH (Easton Pharmaceuticals) Beneish M-Score: 0.00 (As of Jun. 26, 2026)

What is Easton Pharmaceuticals Beneish M-Score?

Easton Pharmaceuticals EAPH -95.00% 12 Beneish M-Score is 0.00 as of Jun. 26, 2026. GuruFocus rates EAPH with a GF Score™ of 12/100.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Easton Pharmaceuticals's Beneish M-Score or its related term are showing as below:

During the past 7 years, the highest Beneish M-Score of Easton Pharmaceuticals was 0.00. The lowest was 0.00. And the median was 0.00.

Easton Pharmaceuticals Beneish M-Score Related Terms

Easton Pharmaceuticals Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Easton Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Easton Pharmaceuticals Beneish M-Score Chart

Easton Pharmaceuticals Annual Data

Trend

Dec01

Dec02

Dec03

Dec04

Dec18

Dec19

Dec20

Beneish M-Score

Get a 7-Day Free Trial

-5.14

-9.34

-5.25

6.33

2.80

Easton Pharmaceuticals Quarterly Data
	Jun02	Sep02	Dec02	Mar03	Jun03	Sep03	Dec03	Mar04	Jun04	Sep04	Dec04	Mar05	Jun05	Sep05	Dec18	Dec19	Dec20	Mar21	Jun21	Sep21
Beneish M-Score	Get a 7-Day Free Trial															6.33	2.80	7.88	-3.88	-2.82

EAPH vs FPSUF, GCAN, ACUR: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Easton Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Easton Pharmaceuticals Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Easton Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Easton Pharmaceuticals's Beneish M-Score falls into.

Save Embed

12GF Score

Easton Pharmaceuticals Inc EAPH

Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Easton Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Easton Pharmaceuticals for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 *

0.528 *

0.404 *

0.892 *

0.115 *

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 *

4.679 *

0.327 *

This Year (Sep21) TTM:

Last Year (Dec19) TTM:

Total Receivables was $0.00 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Current Assets was $0.00 Mil.
Total Assets was $9.97 Mil.
Property, Plant and Equipment(Net PPE) was $0.00 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.00 Mil.
Selling, General, & Admin. Expense(SGA) was $0.26 Mil.
Total Current Liabilities was $0.23 Mil.
Long-Term Debt & Capital Lease Obligation was $2.84 Mil.
Net Income was -0.084 + -0.08 + -0.097 + 0 = $-0.26 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = $0.00 Mil.
Cash Flow from Operations was -0.059 + -0.003 + -0.079 + 0 = $-0.14 Mil.

Total Receivables was $0.00 Mil.
Revenue was 0 + 0 + 0.095 + 0.044 = $0.14 Mil.
Gross Profit was 0 + 0 + 0.095 + -0.027 = $0.07 Mil.
Total Current Assets was $0.25 Mil.
Total Assets was $17.17 Mil.
Property, Plant and Equipment(Net PPE) was $6.98 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.04 Mil.
Selling, General, & Admin. Expense(SGA) was $0.84 Mil.
Total Current Liabilities was $1.46 Mil.
Long-Term Debt & Capital Lease Obligation was $8.46 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(0 / 0)	/	(0 / 0.139)
	=		/	0
	=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(0.068 / 0.139)	/	(0 / 0)
	=	0.489209	/
	=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (0 + 0) / 9.968)	/	(1 - (0.25 + 6.98) / 17.172)
	=	1	/	0.578966
	=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	0	/	0.139
	=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(0.038 / (0.038 + 6.98))	/	(0 / (0 + 0))
	=	0.005415	/
	=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(0.261 / 0)	/	(0.839 / 0.139)
	=		/	6.035971
	=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((2.837 + 0.233) / 9.968)	/	((8.459 + 1.455) / 17.172)
	=	0.307986	/	0.577335
	=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(-0.261 - 0	-	-0.141)	/	9.968
	=	-0.012039

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →

What does a Beneish M-Score of 0.00 mean?

Easton Pharmaceuticals (EAPH) has a Beneish M-Score of 0.00 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Easton Pharmaceuticals and its competitors.

Is Easton Pharmaceuticals' Beneish M-Score too high?

Easton Pharmaceuticals' current Beneish M-Score is 0.00. Overall, Easton Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.

How does Easton Pharmaceuticals' Beneish M-Score compare to FPSUF and GCAN?

Easton Pharmaceuticals' Beneish M-Score of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Beneish M-Score for a Drug Manufacturers company?

A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Beneish M-Score mean?

A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Easton Pharmaceuticals and its competitors. Easton Pharmaceuticals's current Beneish M-Score is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Easton Pharmaceuticals stock overvalued right now?

Easton Pharmaceuticals (EAPH) has a current Beneish M-Score of 0.00. The current Beneish M-Score is 0.00. Easton Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Beneish M-Score calculated?

Beneish M-Score is calculated from a company's financial statements. For Easton Pharmaceuticals (EAPH), the current Beneish M-Score is 0.00 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Easton Pharmaceuticals Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies FPSUF GCAN ACUR ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4507 CTLT SZSE:000538 NSE:DIVISLAB TSE:4523 XSWX:VIFN VTRS SHSE:600196 NBIX SZSE:000963 HKSE:03692 SZSE:002001

Address 2 Bloor Street East, Suite 3500, Toronto, ON, CAN, M4W 1A8

Website https://www.eastonpharmaceuticalsinc.com

Easton Pharmaceuticals Inc is a diversified specialty pharmaceutical company. It owns and develops proprietary transdermal delivery technology and therapeutic over the counter products and drugs to treat cancer and other diseases. The company also owns exclusive distribution rights in Mexico and Latin America for patented women's diagnostic and preventative care products. It is focused on the development of product Viorra. The firm's products include Nauseasol, Skin Renou HA, Kenestrin gel, and XILIVE, among others.

12GF Score

Get the complete analysis for EAPH

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00

Price

View EAPH Analysis

See Beneish M-Score data for all stocks →